MIOBOX: Has the Diabetes Digital Health Gateway Finally Opened?

“The Seemingly Beautiful” Internet Healthcare Market for Diabetes

Amid the booming development of the entire internet healthcare industry, a wide variety of software and hardware products for diabetes health management are flourishing. VCBeat’s Internet Research Institute has previously published an analysis on diabetes apps, revealing that there are nearly 100 mobile applications alone in China. However, the various problems existing in the current diabetes product market cannot be ignored.

It is understood that diabetes management mobile applications currently available on the Chinese market, which use diabetes care as their entry point, enable patients to record blood glucose and other test results, while providing users with relevant glycemic control guidance and remote consultations. Homogenization is a prominent issue among these applications; the figure below presents a functional comparison of several representative apps.

Furthermore, no small number of companies have chosen to enter the market through glucose meters, the hardware with the highest penetration rate among diabetic patients. The basic strategy of these companies is to migrate users from scratch to their own ecosystems by encouraging patients to purchase and use new smart hardware. However, given that Type 2 diabetes patients account for 95% of China’s diabetic population, are generally older, and prioritize the accuracy of glucose meters, it is nearly an impossible task to disrupt the traditional glucose meter market with smart features.

So, where lies the next big opportunity in internet-based healthcare for diabetes?

According to VCBeat, a new product soon to be launched—MIOBOX (Miyou Box) from Tianjin Guanyi Biotechnology Co., Ltd.—aims to find a shortcut to rapidly transition traditional diabetes patients into mobile health users.

Will Miyou Box Be the Cure for the Critical Flaws in the Internet Healthcare Market for Diabetes?

Wu Guanli, co-founder of Tianjin Guanyi Biotechnology, told VCBeat that the company’s new product, MIOBOX (Chinese name: Miyou Box), is a middleware solution connecting traditional mainstream blood glucose meters with smartphones. It enables users to aggregate current and historical blood glucose readings from their meters and automatically transmit the data to a mobile app via wireless signals. Users can also customize, view, and export charts of blood glucose trends with a single click, facilitating simpler, faster, and more intuitive continuous monitoring of blood glucose fluctuations.

The product offers strong scalability and is currently compatible with the best-selling brands and models on the market, such as Roche, Johnson & Johnson, and Abbott. In the future, it will rapidly expand support for other brands and models and open its APIs to enable integration of more third-party medical devices, including blood glucose meters and blood pressure monitors. Combined with a companion mobile app called "MiYou" (Honey Friend), the system also enables data-driven recommendations and social features for individuals with diabetes, thereby delivering peer education with clinical value.

Grounded Investment Opportunities in Innovative Models

Regarding the core values of Miyou Box, Wu Guanli stated that they include the following aspects:

- Build a high-speed on-ramp: The Miyou Box can rapidly onboard the core user base of traditional mainstream blood glucose meters—characterized by a large population, high purchasing power and willingness, and elevated education levels—into the mobile application through the simplest methods and at low cost, thereby establishing a robust moat for deepened value creation driven by user scale.

- Activate the installed base of mainstream blood glucose meters: Partner with blood glucose product manufacturers and distributors to form strategic alliances, leveraging channel resources to drive future mobile health collaborations;

- Establish a closed-loop ecosystem: Rapidly build a new ecosystem for the diabetes industry through an innovative business model. This industrial chain encompasses stakeholders such as distributors of blood glucose meters and related consumables, healthcare providers including hospitals and physicians, individuals with diabetes, insurance companies, and government agencies. Within this symbiotic and mutually beneficial industrial ecosystem, each stakeholder possesses sufficient incentive to drive the operation and continuous improvement of the system:

- Diabetic patients: The affordable Miyou Box requires minimal incremental investment from users, offering simple, intuitive, and valuable data analytics to maximize return on investment and foster habitual adherence to continuous monitoring.

- Channel Partners: Including wholesalers, retailers, pharmaceutical companies, and medical device manufacturers within the blood glucose meter supply chain. Miyou Box can expand cross-selling categories, increase average transaction value and profits, and boost sales of consumables by increasing users' frequency of blood glucose meter usage.

- Hospitals, physicians, and other healthcare providers: Through the Miyou Box, users have the simplest and most accurate method for continuous monitoring of key health indicators, enabling effective remote consultations and post-discharge follow-ups, thereby significantly advancing mobile-based communication between doctors and patients.

- Insurance Companies and Government Agencies: In the future, insurance companies and government agencies can distribute "Miyou Boxes" to target populations on a large scale, leveraging big data analytics for monitoring and control, thereby developing more commercial insurance products or formulating more reasonable medical insurance policies.

As a middleware product, Miyou Box boasts the industry’s first data integration capability. It is well known that internet healthcare projects typically struggle to achieve the short-term explosive growth seen in ordinary mobile internet ventures. However, by adopting a middleware model to penetrate the market from the edge, it becomes possible to rapidly acquire healthcare users at low cost. By helping users effectively overcome the biggest barrier to continuous glucose monitoring, facilitating rapid user migration, and establishing a closed-loop industrial ecosystem, the platform can build unique commercial value and competitive barriers. This represents a pragmatic investment opportunity under an innovative business model.

According to Wu Guanli, the Miyou Box will launch a crowdfunding campaign on JD.com in mid-March and officially hit the market in May, with a price tag under RMB 100.

VCBeat also wishes the Miyou Box a successful launch and will continue to closely monitor the product’s progress.

(To stay updated on the latest internet healthcare startup information, please follow VCBeat’s WeChat official account: vcbeat. We also welcome you to engage with us on topics of interest, contact us via WeChat, and share your startup projects or related research insights.)